Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio
JERUSALEM, September 27, 2011/PRNewswire-FirstCall/ --Oramed Pharmaceuticals Inc. (OTC BB: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced that EnteraBio Ltd. recently reported successful Phase 1 clinical trial results. The Phase 1 data supports the continued development of Entera's oral osteoporosis drug.
Entera's IP was out-licensed from Oramed in 2010 and Oramed is
entitled to 3% royalties plus a small holding in the company
according to the agreement.
EnteraBio is developing an oral tablet form of a well known
osteoporosis drug, which currently totals $830 million in annual
sales. The Phase 1 clinical trial consisted of twelve healthy
patients and was conducted at the Hadasah Medical Center in
Jerusalem. No adverse events were reported.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes
through its patented flagship product, an orally ingestible insulin
capsule currently in Phase 2 clinical trials. Established in 2006,
Oramed's technology is based on over 25 years of research performed
by top research scientists at Jerusalem's Hadassah Medical Center.
Oramed's corporate and R&D headquarters are based in
Jerusalem.
For more information, please visit http://www.oramed.com
About EnteraBio
Entera Bio is developing novel oral drugs by utilizing its
proprietary cutting edge delivery technology. This technology
protects large molecules and peptides in the GI tract. Oral drug
delivery is the most straight forward and user friendly approach to
medical treatment. Entera Bio has key personnel with the relevant
know how, experience and networks working together to enable rapid
development of its products. The company has an experienced
management team with more than 50 years of combined drug
development experience.
For more information, please visit http://www.enterabio.com
SafeHarbor Statement
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the Company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the Company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the Company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the Company to
differ materially from those expressed or implied in such forward
looking statements. The Company undertakes no obligation to update
or revise any forward-looking statements.
Company and Investor Relations Contacts:
Oramed Pharmaceuticals
Tara Horn
Office: +1-646-240-4193
Cell: +972-54-334-4318
Email: tara@oramed.com
Source: Oramed Pharmaceuticals Inc.
Posted: September 2011
